Introduction
============

The frequent presence of academic, behavioral and cognitive difficulties in children with sleep disordered breathing (SDB) has led to greatly increased awareness to this condition. In recent years, the cardiovascular system has been more systematically explored in the context of SDB, and the endothelium has emerged as a major, if not the major cellular target for injury in this disease. In this review, I will discuss the evidence linking pediatric sleep apnea to endothelial dysfunction.

OSA in Children
===============

Habitual snoring during sleep, the hallmark indicator of increased upper airway resistance, is an extremely frequent occurrence during early childhood, with a prevalence of up to 27% being reported (median 12%; Hultcrantz et al., [@B37]; Ferreira et al., [@B23]; O'Brien et al., [@B62]; Rosen et al., [@B66]; Ersu et al., [@B22]; Kaditis et al., [@B45]; Montgomery-Downs et al., [@B57]; Urschitz et al., [@B72]; Montgomery-Downs and Gozal, [@B56]).

The spectrum of the condition termed "sleep disordered breathing" in children is difficult to define in a precise fashion because the cut-offs of what constitutes disease or not is still the subject of intense debate (Gozal and Kheirandish-Gozal, [@B29]; Spruyt et al., [@B68]). Notwithstanding of such elusive diagnostic criteria, obstructive sleep apnea (OSA) is most common in young children (pre-school and early school years) with a peak prevalence around 2--8 years, and subsequent declines in frequency (Corbo et al., [@B14]).In children, the two major pathophysiological determinants of OSA are enlargement of tonsils and adenoids and obesity. Indeed, the rather accelerated increase over the last two decades in the prevalence of pediatric obesity has led to substantial changes in the cross sectional demographic and anthropometric characteristics of the children being referred for evaluation of habitual snoring. For example, while \<15% of all symptomatic habitually snoring children were obese (i.e., body-mass index *z* score \>1.57) in the early 1990's, \>50% fulfilled such criteria among all clinical referrals for suspected OSA in the last 2--3 years at our Sleep Center (Gozal et al., [@B33]). A substantial body of evidence has accumulated in the last decades to rather conclusively suggest that SDB can lead to substantial morbidities affecting CNS, cardiovascular and metabolic systems, and somatic growth, ultimately leading to significant reductions in the quality of life (Dayyat et al., [@B15]) Furthermore, it is likely that the concomitant presence of obesity and OSA will potentiate such morbidities, suggesting that they may be targeting similar cellular substrates whose dysfunction may underlie the end-organ morbidities seen in SDB (Bhattacharjee et al., [@B11]; Spruyt and Gozal, [@B67]).

Cardiovascular Morbidity of Pediatric OSA
=========================================

Similar to adults, OSA in children has now been associated with an increased risk for cardiovascular morbidities, albeit with reduced phenotypic severity, most likely the corollary of the better compensatory vascular capacitance in children. For example, increased prevalence of altered blood pressure regulation (Amin et al., [@B3]), systemic hypertension, (Marcus et al., [@B55]; Enright et al., [@B21]; Kohyama et al., [@B51]), and changes in left ventricular geometry, (Amin et al., [@B4], [@B5]), have all now been described in children with OSA, and appear to be severity-dependent (Aljadeff et al., [@B2]). The mechanisms mediating cardiac and blood pressure changes are most likely associated with the increases in sympathetic activity and reactivity that progressively develop in the context of OSA (Baharav et al., [@B7]; O'Brien and Gozal, [@B61]; Hakim et al., [@B34]). In addition, recent evidence supports the assumption of potential endothelial dysfunction in children with OSA, as evidenced by increases in the circulating levels of several adhesion molecules (O'Brien et al., [@B63]). Parenthetically, the endothelial dysfunction associated with OSA is most likely the result of initiation and propagation of oxidative stress and inflammatory responses within the microvasculature (Hansson, [@B35]).

For example, C-reactive protein, which has been traditionally linked to increased risk for cardiovascular disease even if such assumption has been recently challenged, (Elias-Smale et al., [@B20]; Kovacs et al., [@B52]) provides a good systemic marker for the presence of inflammation. In a series of recent studies, plasma concentrations of C-reactive protein were elevated in a severity-dependent fashion among children and adolescents with OSA, even after correction for body-mass index (Tauman et al., [@B71]; Larkin et al., [@B53]; Kheirandish-Gozal et al., [@B48]). Only one study by Kaditis et al. ([@B44]) failed to identify these relationships in a study of Greek children.

Therefore, it is highly probable that OSA will elicit a variable, yet significant systemic inflammatory response, which in turn may initiate and propagate atherogenetic mechanisms. In support of this assumption, three major recent studies from our laboratory revealed the following:

1.  IL-6 levels were higher and IL-10 plasma levels were lower in non-obese children with OSA and returned to control levels after treatment with surgical tonsillectomy and adenoidectomy (T&A; Gozal et al., [@B28]).

2.  Evidence for flow-dependent reperfusion abnormalities indicative of endothelial dysfunction was identified in non-obese children with OSA, and was reversed in most cases after adenotonsillectomy (T&A; Gozal et al., [@B32]; see below).

3.  Endothelial dysfunction and neurocognitive deficits are highly overlapping phenomena in pediatric OSA. Thus, both of these morbid consequences may share similar pathogenetic mechanisms involving the endothelium as the primary process driving neuronal dysfunction (Gozal et al., [@B31]).

In the context of the epidemic of childhood obesity, we have also recently shown that obesity alone elicits endothelial dysfunction, and that obesity and OSA will interact and potentiate the adverse functional consequences on the endothelium (Kheirandish-Gozal et al., [@B48]; Gozal et al., [@B27]).

This is a particularly important issue, since the presence of early cardiovascular risk factors in childhood has been linked to decreased survival and increased cardiovascular morbidity later in life (Berenson et al., [@B9]).

Alterations in Endothelial Function in Pediatric OSA
====================================================

In addition to autonomic nervous system changes, the systemic inflammatory pathways activated in the presence of OSA could induce functional and structural disruption of the endothelium (Figure [1](#F1){ref-type="fig"}). Indeed, reductions in brachial artery flow-mediated dilation, a surrogate marker of endothelial functional integrity, have been reported in adults with OSA (Kato et al., [@B46]; Nieto et al., [@B59]; Oflaz et al., [@B64]) and were improved after treatment with CPAP (Ip et al., [@B38]; Ohike et al., [@B65]; Lattimore et al., [@B54]).

![**Schematic diagram displaying the activation of injurious pathways in the vasculature as related to OSA**. The activation of these pathways coordinates then a variety of cascades leading to reduced nitric oxide bioavailability, endothelial damage and dysfunction, shedding of apoptotic endothelial cells, and migration of monocytes and macrophages to form foam cells and promote atherosclerosis. In parallel with such events, release of a variety of chemokines and pro-angiogenic agents, such as VEGF may be prompted by some subsets of cell-derived microparticles or exosomes, and may lead to recruitment, migration, and homing to the damaged endothelium of multiple sub-populations of bone marrow resident stem cells that have the potential to repair the injured endothelium and either mitigate or induce a regain of vascular function (green background triangles).](fneur-03-00092-g001){#F1}

Similar findings were also communicated on younger adult patients with OSA who were free of any known cardiovascular involvement, and as previously shown, CPAP treatment resulted in reversal of endothelial dysfunction (Itzhaki and Wertheimer, [@B40]; Itzhaki et al., [@B39]).

Endothelial functional changes have also emerged as a frequent complication of obesity (Suheyl et al., [@B69]; Bhattacharjee et al., [@B10]) and diabetes (Valle Jimenez et al., [@B73]), and these are important issues considering the increased prevalence of OSA in obese children (Tauman and Gozal, [@B70]; Kaditis et al., [@B43]; Verhulst et al., [@B76], [@B75]; Bixler et al., [@B12]; Dayyat et al., [@B16]) and also the potential interactions between obesity and OSA to amplify end-organ dysfunction (Gozal and Kheirandish-Gozal, [@B30]; Kim et al., [@B50]).

I am only aware of a paucity of studies, all of which originated from our laboratory that have thus far explored whether OSA adversely impacts on endothelial function in children. The initial study explored endothelial function in 26 non-obese children with OSA using a novel approach to the post-occlusion hyperemic response test. In this study, endothelial function was significantly impaired when compared to healthy controls. Furthermore, significant improvements or complete normalization of endothelial function occurred 6 months after treatment of OSA with adenotonsillectomy in the majority of the children. However, the presence of a strong family history of early onset cardiovascular disease in six of the 26 children was associated with no improvements in endothelial function after adenotonsillectomy (Gozal et al., [@B32]).

This observation, if repeated in other cohorts, would position OSA not only as a major trigger for disruption of vascular function in genetically predisposed children, but also for initiating a cascade of vascular events in these children that would be more difficult if not impossible to reverse, leading to earlier onset and increased severity of cardiovascular diseases during adulthood. In a subsequent study, we found that obesity and OSA appear to potentiate the magnitude of endothelial damage possibly via activation of systemic inflammatory pathways, as evidenced by MRP 8/14 and CRP levels (Kim et al., [@B50]).

Endothelial Progenitor Cells
============================

Although in pediatric OSA significant increases in established soluble molecules reflecting alterations of the main regulatory functions of the endothelium such as inflammation, hemostasis, or permeability are found, these markers have been somewhat disappointing by their lack of specificity and clinical relevance at the individual level. The capacity of the adherent endothelium to undergo cellular alterations has provided insights on the endothelium as being a dynamic tissue in equilibrium with a circulating compartment reflecting both lesion and regeneration of the vascular tree. This endothelial-derived compartment has led to delineate a third group of cellular markers, corresponding to circulating endothelial cells (CEC) and endothelial-derived microparticles (EMP) released from the injured vessels and also progenitors endothelial progenitor cells (EPC).

Described 30 years ago as inert "cellular dust" cell-derived microparticles (MPs) are considered to be microvesicles (0.05--1 μm) released through the process of exocytic budding of the plasma membrane following stimulation of different cell types (Hugel et al., [@B36]; Nomura et al., [@B60]).

There are two well-known cellular processes that can lead to the formation of MPs: chemical and physical cell activation (by agonists or shear stress, respectively), and apoptosis. However, the mechanisms that take place during MP formation are not completely elucidated. An asymmetric distribution of phospholipids is generated during membrane biogenesis; this asymmetry is lost after cell stimulation, and several studies suggest that this is necessary for MP formation. In normal persons, EMPs represent a minority of total circulating MP. Flow cytometry is the most widely used method to characterize EMPs, but the pro-coagulant function of EMP can also be measured using functional assays (based on coagulation activation by MP derived phospholipids and/or TF), and these two complementary approaches have been recently reviewed in a forum aiming to establish standards in measurement techniques and reporting methods (Jy et al., [@B42]; Freyssinet and Dignat-George, [@B24]).

Using state-of-the-art consensus approaches we have provided compelling support to the notion that MP's are increased in pediatric OSA (Kim et al., [@B49]), whereby we showed that endothelial MPs and endothelial progenitor MPs, leukocyte MPs, and platelet MPs levels are all significantly different according to severity of OSA in children. Furthermore, platelet-derived MPs emerge as independent contributors to the vascular dysfunction associated with OSA in children and may account for increased risk for altered endothelial function (Kim et al., [@B49]).

Current understanding supports the view that CEC are mature cells shed from the vessel wall in response to injury (Blann et al., [@B13]).These cells present a heterogeneous size (from 10 to 50 micron), express endothelial markers (von Willebrand factor \[vWF\], CD31, CD144) but are negative for leukocyte markers. In contrast to EPC, they do not express immature markers such as CD133, and do not give rise to cell colonies with a high proliferative potential. Due to the extreme scarcity of CEC in peripheral blood, an important step in their identification has been the development of sensitive technologies for the detection of rare events based on the immunolabeling with monoclonal antibodies to novel endothelial antigens (George et al., [@B26]; Woywodt et al., [@B79]). In 1992, an antibody recognizing the CD146 antigen combined with an immuno-magnetic separation assay allowed the immunological characterization of CEC in the peripheral blood of patients submitted to coronary angioplasty chosen as a model of vascular injury. The marked elevation of CEC number found after angioplasty, confirmed that they result from endothelial trauma triggered by the catheter procedure itself (George et al., [@B25]).

Thus, CEC are sensitive indicators of endothelial cell damage, and could provide important insights into OSA-induced vascular dysfunction. We are currently unaware of any published studies on CEC in pediatric OSA.

In 1997, Asahara et al. ([@B6]) initially reported that that purified CD34 positive hematopoietic progenitor cells from adults were able to differentiate *ex vivo* to an endothelial cell phenotype .

These cells were named "endothelial progenitor cells" (EPC), and showed expression of various endothelial markers (Asahara et al., [@B6]). Circulating EPC have emerged as an important marker associated with cardiovascular risk profile and physical fitness (Vasa et al., [@B74]; Werner et al., [@B77]).

Endothelial progenitor cells originate from bone marrow stem cells through a chemokine-dependent gradient involving stromal differentiation factor 1 (SDF1; also known as CXC chemokine ligans 12) and its ligand receptor CXC chemokine receptor4 (CXCR4), and such factors appear to be determined not only by SDF1 gene variation but also by the response to specific stimuli such as hypoxia (Aiuti et al., [@B1]; Benboubker et al., [@B8]; Moore et al., [@B58]; De Falco et al., [@B17]; Dimmeler and Zeiher, [@B18]; Doyle et al., [@B19]; Werner and Nickenig, [@B78]; Xiao et al., [@B80]).

Endothelial progenitor cells are involved in neovessel formation and endothelial regeneration, with reduced levels and functional impairment of EPCs being correlated with the presence of coronary artery disease (Benboubker et al., [@B8]; De Falco et al., [@B17]).

Recent work by Jelic and colleagues has shown that OSA in adult patients is not only associated with abnormal endothelial function and increased inflammatory and oxidative stress responses, but is also accompanied by reduced numbers of circulating EPC. Furthermore, treatment of OSA with CPAP resulted in improvement of endothelial function and concomitant increases in the number of circulating EPC (Jelic et al., [@B41]).

As mentioned above, we have reported on the presence of endothelial dysfunction on non-obese children with OSA (Gozal et al., [@B32]) and that effective treatment of OSA resulted in reversal of endothelial dysfunction in approximately 80% of these children. While genetic predisposition of premature cardiovascular disease could be a factor associated in the lack of improved endothelial function in these children (Gozal et al., [@B32]) the possibility exists that the underlying EPC and SDF1 responses to OSA may also contribute to endothelial repair. Furthermore, a substantial degree of variability is present in the time to peak reperfusion after a 60 s-brachial occlusion maneuver in children with OSA, suggesting that the magnitude of endothelial dysfunction may be explained at least in part by the number of circulating EPC (Kheirandish-Gozal et al., [@B47]).

Summary
=======

Taken together, a causative link between OSA and endothelial dysfunction in children is likely, and deserves further exploration including identification of mechanisms underlying this potential morbidity. Based on aforementioned considerations, delineation of such mechanisms will need to account for processes that mediate injury and also for those that promote vascular repair and functional integrity (Figure [1](#F1){ref-type="fig"}). Although the deleterious effects of OSA on such systems may be reversed by early diagnosis and treatment, the epidemic of childhood obesity is likely to aggravate this problem, and therefore, improved techniques aiming to establish the endothelial phenotype in the context of clinical practice need to be developed, such as to enable risk assessment and optimal interventions, aiming to prevent the adverse consequences of such alterations on morbidity and mortality later in life.
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